9853 Pacific Heights Blvd.
Suite D. San Diego,
CA 92121, USA
Tel: 858-263-4982
Email: info@abeomics.com

14-1011: Human Peripheral Blood CD19+/CD27- Naive B Cells(Discontinued)

Description

Peripheral blood CD19+CD27- naïve B cells are B cells that have not encountered an antigen. Upon antigen contact naïve B cells will undergo isotype class-switch recombination and somatic hypermutation and develop into plasma and memory B cells.

Human CD19+CD27- naïve B cells are isolated from peripheral blood mononuclear cells by means of negative selection. Cells expressing CD2, CD3, CD14, CD16, CD27, CD36, CD43, CD56, CD66b, and CD235a are depleted from the mononuclear cell population using immunomagnetic particles leaving purified, untouched CD19+CD27- naïve B cells. Isolated cells are characterized by flow cytometry to ensure a highly pure and viable cell population.

Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.

Product Info

Amount :	1 Vial
Content :	Each cryopreserved vial contains 0.5 million cells. Preserved in CryoStorâ„¢ CS10 (10% DMSO)
Storage condition :	Immediately upon receipt, store in liquid nitrogen.

Application Note

LIMITED USE RESTRICTIONS:

THIS PRODUCT IS SOLELY FOR IN VITRO RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

By use of this product, user agrees to be bound by the terms of this limited use statement.

This product is solely for Internal Research Purposes and not for Commercial Purposes. Commercial Purposes include, but are not limited to (1) use of the cell line in manufacturing; (2) use of the cell line to provide a service, information or data; (3) use of the cell line for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the cell line whether or not such cell lines are resold for use in research.

Commercial License Agreement is available for non-research use if applicable. Please contact Abeomics (info@abeomics.com).

9853 Pacific Heights Blvd.
Suite D. San Diego,
CA 92121, USA
Tel: 858-263-4982
Email: info@abeomics.com